Clinical Pharmacogenomics of Antidepressant Response

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Health Research Institutes, Taiwan
• Collaborators: Chang Gung Memorial Hospital; Mackay Memorial Hospital; National Science Council, Taiwan; Song-De, Taipei City Hospital, Taiwan; Taipei City Hospital; Taipei Medical University WanFang Hospital
• Treatments: Antidepressive Agents; Citalopram; Paroxetine

Criteria

Inclusion Criteria:

• self-identified as of Taiwanese/Chinese ethnic background, and report that both of their parents and all four or three of their grandparents are members of the same ethnic group;

• HAMD-21 > 17 plus MDE (i.e., current major depressive episode) based on SCID;

• male or female, who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devises or abstinence;

• age >= 18;

• capable of giving informed consent;

Exclusion Criteria:

• diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, bipolar disorders;

• current drug or alcohol abuse or dependence or history of drug or alcohol abuse or dependence within the past 6 months;

• unstable medical or neurological conditions that are likely to interfere with the treatment of depression;

• history of allergy to antidepressants;

• history of seizure disorder;

• pregnancy;

• active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study;